Home>
US Stocks>
Acadia Pharmaceuticals

Acadia Pharmaceuticals share price today

(ACAD)

Acadia Pharmaceuticals share price is $18.66 & ₹1,599.91 as on 3 Jan 2025, 2.30 'hrs' IST

$18.66

▲

0.31

(1.69%)

Market is closed - opens 8 PM, 03 Jan 2025

View live Acadia Pharmaceuticals share price in Dollar and Rupees. Guide to invest in Acadia Pharmaceuticals from India. Also see the sentimental analysis on Indian investors investing in Acadia Pharmaceuticals. Get details on the Indian mutual funds that are investing in Acadia Pharmaceuticals. Get Analyst recommendations and forecasts along with all the Acadia Pharmaceuticals's financials.

Acadia Pharmaceuticals share price movements

Today's Low: $18.51
Today's High: $19.37
$18.66
0.83%
Downside
Day's Volatility :4.47%
Upside
3.67%
52 Weeks Low: $14.15
52 Weeks High: $31.10
$18.66
24.17%
Downside
52 Weeks Volatility :54.5%
Upside
40.0%

Acadia Pharmaceuticals Returns

Period	Acadia Pharmaceuticals Inc.	Sector (Health Care)	Index (Russel 2000)
3 Months	21.52%	-10.0%	0.0%
6 Months	13.76%	-4.7%	0.0%
1 Year	-38.73%	-0.9%	0.0%
3 Years	-22.31%	-2.4%	-21.2%

Acadia Pharmaceuticals Key Statistics

in dollars & INR

Previous Close	$18.35
Open	$18.45
Today's High	$19.37
Today's Low	$18.505
Market Capitalization	$3.1B
Today's Volume	$5.8M
52 Week High	$31.1
52 Week Low	$14.15
Revenue TTM	$929.2M
EBITDA	$124.5M
Earnings Per Share (EPS)	$0.78
PE Ratio	23.53
Profit Margin	13.83%
Quarterly Earnings Growth YOY	28.35%
Return On Equity TTM	27.36%

How to invest in Acadia Pharmaceuticals from India?

It is very easy for Indian residents to invest directly in Acadia Pharmaceuticals from India. Indian investors can open a free US stocks account on the INDmoney app. You can find live prices of the Acadia Pharmaceuticals stock in both Indian Rupees (INR) and US Dollars (USD). Search for Acadia Pharmaceuticals or ACAD on the INDmoney app and click on Buy or SIP. You can invest by choosing quantities of shares of Acadia Pharmaceuticals or rupee/ dollar value or set up a fixed SIP amount to be invested every month or week.

For example: You can easily buy Rs.100 worth of Acadia Pharmaceuticals shares which would translate to 0.046 fractional shares of Acadia Pharmaceuticals as of today. Learn more about fractional investing.

Indians can now also easily transfer and add money to their US stocks account via the INDmoney app. Invest in US Stocks from India, including recognised companies like Acadia Pharmaceuticals, in just a few clicks!

Returns in Acadia Pharmaceuticals for Indian investors in Rupees

Investment Value

₹1,00,000

Acadia Pharmaceuticals investment value today

Current value as on today

₹65,279

Returns

₹34,721

(-34.72%)

Returns from Acadia Pharmaceuticals Stock

₹37,696 (-37.7%)

Dollar Returns

₹2,975 (+2.97%)

Indian investors sentiment towards Acadia Pharmaceuticals

25%

Period: Oct 4, 2024 to Jan 2, 2025. Change in 30 Days versus previous period

Search volume for Acadia Pharmaceuticals on INDmoney from India has grown in the last 30 days as on Jan 3, 2025. 25% more investors are searching Acadia Pharmaceuticals in the last 30 days versus the previous period.

Global Institutional Holdings in Acadia Pharmaceuticals

Baker Bros Advisors LP
25.77%
Vanguard Group Inc
8.32%
RTW INVESTMENTS, LLC
8.24%
BlackRock Inc
7.25%
State Street Corp
3.59%
D. E. Shaw & Co LP
2.11%

Analyst Recommendation on Acadia Pharmaceuticals

Buy

73%Buy

23%Hold

3%Sell

Based on 26 Wall street analysts offering stock ratings for Acadia Pharmaceuticals(by analysts ranked 0 to 5 stars)

Based on 26 analyst

Current
1M Ago
3M Ago

Buy

Hold

Sell

Analyst Forecast on Acadia Pharmaceuticals

What analysts predicted

Upside of 34.54%

Current:

$18.66

Target:

$25.11

Insights on Acadia Pharmaceuticals

Price Movement
In the last 7 days, ACAD stock has moved up by 5.6%
Increasing Revenue
Revenue is up for the last 3 quarters, 205.83M → 250.40M (in $), with an average increase of 9.2% per quarter
Decreasing Net Profit
Netprofit is down for the last 2 quarters, 33.38M → 32.76M (in $), with an average decrease of 1.9% per quarter
ACAD vs ALNY (1 yr)
In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 20.7% return, outperforming this stock by 61.2%
ACAD vs VRTX (3 yr)
In the last 3 years, Vertex Pharmaceuticals Incorporated has given 38.8% return, outperforming this stock by 60.2%
Price to Sales
ForACAD every $1 of sales, investors are willing to pay $3.3, whereas for Alnylam Pharmaceuticals, Inc., the investors are paying $14.2 for every $1 of sales.

Acadia Pharmaceuticals Financials in INR & Dollars

	FY18	Y/Y Change
Revenue	$223.8M	↑ 79.19%
Net Income	$-245.2M	↓ 15.28%
Net Profit Margin	-109.56%	↑ 122.15%

	FY19	Y/Y Change
Revenue	$339.1M	↑ 51.5%
Net Income	$-235.3M	↓ 4.05%
Net Profit Margin	-69.38%	↑ 40.18%

	FY20	Y/Y Change
Revenue	$441.8M	↑ 30.28%
Net Income	$-281.6M	↑ 19.69%
Net Profit Margin	-63.74%	↑ 5.64%

	FY21	Y/Y Change
Revenue	$484.1M	↑ 9.6%
Net Income	$-167.9M	↓ 40.38%
Net Profit Margin	-34.67%	↑ 29.07%

	FY22	Y/Y Change
Revenue	$517.2M	↑ 6.83%
Net Income	$-216.0M	↑ 28.66%
Net Profit Margin	-41.76%	↓ 7.09%

	FY23	Y/Y Change
Revenue	$726.4M	↑ 40.45%
Net Income	$-61.3M	↓ 71.62%
Net Profit Margin	-8.44%	↑ 33.32%

	Q2 FY23	Q/Q Change
Revenue	$165.2M	↑ 39.48%
Net Income	$1.1M	↓ 102.59%
Net Profit Margin	0.67%	↑ 36.99%

	Q3 FY23	Q/Q Change
Revenue	$211.7M	↑ 28.12%
Net Income	$-65.2M	↓ 5950.63%
Net Profit Margin	-30.79%	↓ 31.46%

	Q4 FY23	Q/Q Change
Revenue	$231.0M	↑ 9.14%
Net Income	$45.8M	↓ 170.27%
Net Profit Margin	19.82%	↑ 50.61%

	Q1 FY24	Q/Q Change
Revenue	$205.8M	↓ 10.91%
Net Income	$16.6M	↓ 63.85%
Net Profit Margin	8.04%	↓ 11.78%

	Q2 FY24	Q/Q Change
Revenue	$242.0M	↑ 17.55%
Net Income	$33.4M	↑ 101.69%
Net Profit Margin	13.8%	↑ 5.76%

	Q3 FY24	Q/Q Change
Revenue	$250.4M	↑ 3.49%
Net Income	$32.8M	↓ 1.87%
Net Profit Margin	13.09%	↓ 0.71%

	FY18	Y/Y Change
Profit	$205.5M	↑ 83.72%

	FY19	Y/Y Change
Profit	$319.5M	↑ 55.48%

	FY20	Y/Y Change
Profit	$421.2M	↑ 31.84%

	FY21	Y/Y Change
Profit	$465.0M	↑ 10.4%

	FY22	Y/Y Change
Profit	$507.1M	↑ 9.05%

	FY23	Y/Y Change
Profit	$680.7M	↑ 34.24%

	Q2 FY23	Q/Q Change
Profit	$157.8M	↑ 35.09%

	Q3 FY23	Q/Q Change
Profit	$197.1M	↑ 24.91%

	Q4 FY23	Q/Q Change
Profit	$213.2M	↑ 8.16%

	Q1 FY24	Q/Q Change
Profit	$182.9M	↓ 14.2%

	Q2 FY24	Q/Q Change
Profit	$223.7M	↑ 22.34%

	Q3 FY24	Q/Q Change
Profit	$231.5M	↑ 3.49%

	FY18	Y/Y Change
Operating Cash Flow	$-167.5M	↓ 23.13%
Investing Cash Flow	$-71.5M	↓ 177.31%
Financing Cash Flow	$306.6M	↑ 883.22%

	FY19	Y/Y Change
Operating Cash Flow	$-151.1M	↓ 9.76%
Investing Cash Flow	$-165.8M	↑ 131.97%
Financing Cash Flow	$371.8M	↑ 21.26%

	FY20	Y/Y Change
Operating Cash Flow	$-136.2M	↓ 9.9%
Investing Cash Flow	$192.5M	↓ 216.08%
Financing Cash Flow	$81.0M	↓ 78.22%

	FY21	Y/Y Change
Operating Cash Flow	$-125.7M	↓ 7.72%
Investing Cash Flow	$-71.1M	↓ 136.93%
Financing Cash Flow	$18.2M	↓ 77.58%

	FY22	Y/Y Change
Operating Cash Flow	$-114.0M	↓ 9.25%
Investing Cash Flow	$73.2M	↓ 203.01%
Financing Cash Flow	$8.2M	↓ 54.86%

	Q2 FY23	Q/Q Change
Operating Cash Flow	$8.2M	↓ 145.73%
Investing Cash Flow	$-194.3M	↓ 200.92%
Financing Cash Flow	$5.5M	↑ 273.67%

	Q3 FY23	Q/Q Change
Operating Cash Flow	$-59.0M	↓ 818.88%
Investing Cash Flow	$34.1M	↓ 117.56%
Financing Cash Flow	$12.8M	↑ 132.77%

Acadia Pharmaceuticals Technicals Summary

Sell

Neutral

Buy

Acadia Pharmaceuticals is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

Acadia Pharmaceuticals Vs Peers

Company Name	1 Month	6 Month	1 Year	3 Years	5 Years
Acadia Pharmaceuticals Inc.	12.58%	13.76%	-38.73%	-22.31%	-57.14%
Regeneron Pharmaceuticals, Inc.	-4.97%	-31.12%	-21.91%	15.48%	91.62%
Biontech Se	-1.42%	42.28%	6.01%	-49.15%	155.61%
Alnylam Pharmaceuticals, Inc.	-6.56%	-6.26%	22.36%	42.41%	102.91%
Vertex Pharmaceuticals Incorporated	-11.88%	-15.14%	-3.23%	81.51%	79.75%

Company Name	P/E Ratio	P/B Ratio	PEG Ratio	EPS	ROE	ROA	Div Yield	BVPS
Acadia Pharmaceuticals Inc.	23.53	23.53	-0.42	0.69	0.27	0.09	NA	3.47
Regeneron Pharmaceuticals, Inc.	17.61	17.61	1.06	45.07	0.17	0.07	NA	272.04
Biontech Se	160.8	NA	0.04	-3.11	-0.02	-0.01	NA	79.73
Alnylam Pharmaceuticals, Inc.	NA	NA	-0.49	-0.19	-15.01	-0.03	NA	0.25
Vertex Pharmaceuticals Incorporated	32.84	NA	1.06	0.51	-0.03	0.12	NA	60.65

Company Name	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin
Acadia Pharmaceuticals Inc.	Buy	$3.1B	-57.14%	23.53	13.83%
Regeneron Pharmaceuticals, Inc.	Buy	$78.3B	91.62%	17.61	33.61%
Biontech Se	Buy	$27.3B	155.61%	160.8	-15.36%
Alnylam Pharmaceuticals, Inc.	Buy	$30.4B	102.91%	NA	-15.86%
Vertex Pharmaceuticals Incorporated	Buy	$103.7B	79.75%	32.84	-4.51%

About Acadia Pharmaceuticals

acadia pharmaceuticals (nasdaq: acad) is a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in related central nervous system (cns) disorders. all of acadia's product candidates emanate from internal discoveries. we believe that they offer innovative therapeutic approaches that may provide significant advantages relative to current therapies. acadia’s history is rooted in science and strong leadership in cns research. our proprietary drug discovery platform has led to a portfolio of drug candidates with large unmet needs. since the beginning, we have been dedicated to discovering, developing and commercializing innovative therapies that improve the lives of patients suffering from such disorders. acadia is headquartered in san diego. the city represents the second largest biotechnology industry cluster in the united states, home to over 400 companies, as well as the salk institute for biological studies

Organization	Acadia Pharmaceuticals
Employees	620
CEO	Mr. Mark C. Schneyer
Industry	Health Technology

Management People of Acadia Pharmaceuticals

Name	Title
Mr. Mark C. Schneyer	Executive VP & CFO
Mr. Stephen R. Davis J.D.	Consultant
Mr. Brendan P. Teehan	Non-Executive Employee
Ms. Catherine E. Owen Adams	CEO & Director
Mr. James K. Kihara	VP, Chief Accounting Officer & Corporate Controller
Dr. Elizabeth H.Z. Thompson Ph.D.	Executive VP and Head of Research & Development
Mr. Benir Ruano	Senior Vice President of Technical Development, Operations & Quality
Mr. Albert S. Kildani	Senior Vice President of Investor Relations & Corporate Communications
Ms. Jennifer J. Rhodes J.D.	Executive VP, Chief Legal Officer & Secretary
Mr. Rob Ackles	Senior VP & Chief People Officer

Important FAQs about investing in Acadia Pharmaceuticals from India :

What is Acadia Pharmaceuticals share price today?

Acadia Pharmaceuticals share price today stands at $18.66, Open: $18.45 ; Previous Close: $18.35 ; High: $19.37 ; Low: $18.51 ; 52 Week High: $31.10 ; 52 Week Low: $14.15. The stock opens at $18.45, after a previous close of $18.35. The stock reached a daily high of $19.37 and a low of $18.51, with a 52-week high of $31.10 and a 52-week low of $14.15.

Can Indians buy Acadia Pharmaceuticals shares?

Yes, Indians can invest in the Acadia Pharmaceuticals (ACAD) from India.

With INDmoney, you can buy Acadia Pharmaceuticals at 0 brokerage. The step-by-step process is as follows:

Open your zero cost US Stocks account and zero balance IND linked savings a/c (this can be done in less than 3 minutes)
Transfer funds to your US Stocks account using your IND linked savings a/c (It takes 24 hours excluding Saturday and Sunday). With INDmoney, you get the best INR USD exchange rates.
Once funds are transferred successfully, you can buy Acadia Pharmaceuticals at zero transaction cost.

How can I buy Acadia Pharmaceuticals shares from India?

It is very easy to buy Acadia Pharmaceuticals from India. With INDmoney, you can open a US stocks account in less than 3 minutes. Transfer funds in 24 hours and buy stocks very easily - that too at 0 brokerage. All this is done at 0 account opening & management fee, 0 brokerages, and at the same time you get the best rupee-US dollar exchange rate.

Can Fractional shares of Acadia Pharmaceuticals be purchased?

Yes, you can buy fractional shares of Acadia Pharmaceuticals with INDmoney app.

What are the documents required to start investing in Acadia Pharmaceuticals stocks?

To start investing in Acadia Pharmaceuticals, You will need the following documents:

Proof of Identification (PAN, Aadhaar etc)
Proof of address (Aadhaar, Voter ID etc)

These documents are required as per RBI's guidelines to create your IND linked savings a/c so that you can execute for global fund transfer. The entire process is paperless and can be completed seamlessly.